Is BriaCell Therapeutics Corp. a good investment? BriaCell Therapeutics Corp. (BCTX) is currently trading at 3.39 USD.
Earnings Schedule: BriaCell Therapeutics Corp. is expected to release its next earnings report on Oct. 28, 2026. The market consensus estimate for Forward EPS is -0.39.
No, it does not currently pay a dividend.
BriaCell Therapeutics Corp. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
The next earnings date is projected to be Oct. 28, 2026. The company currently has a trailing EPS of -6.97.
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. The company is headquartered in West Vancouver, Canada.
| Split Date | Split Ratio to 1 |
|---|---|
| Dec. 3, 2014 | 0.307 |
| Jan. 2, 2020 | 1:300 |
| Jan. 29, 2025 | 1:15 |
| Aug. 25, 2025 | 1:10 |
Community Discussion